SCHEMBL3115388

SCHEMBL3115388

COC(=O)c1ccc(OC2CCC(=Cc3ccc(-c4ccccc4)cc3)CC2)c(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.43
ESRRA P11474 1/20 0.43
PDE4A P27815 7/20 0.41
PDE4B Q07343 7/20 0.41
PDE4C Q08493 7/20 0.41
PDE4D Q08499 7/20 0.41
EPHX2 P34913 1/20 0.41
RORC P51449 1/20 0.41
ACLY P53396 1/20 0.40
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
MAPT P10636 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
LMNA P02545 2/20 0.40
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
EGFR P00533 1/20 0.40
ALDH1A1 P00352 1/20 0.39
TAS1R3 Q7RTX0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3116143 0.89 EPHX2 (0.48) PDE4APDE4BPDE4CPDE4DEPHX2
SCHEMBL13158236 0.89 RAB9A (0.48) EPHX2RORCKMT2AMEN1MAPT
SCHEMBL3109712 0.81 MCHR1 (0.45) CYP3A4PDE4APDE4BPDE4CPDE4D
SCHEMBL13158793 0.80 IGF1R (0.38) CYP3A4PDE4APDE4BPDE4CPDE4D
SCHEMBL16544907 0.80 RORC (0.59) PDE4APDE4BPDE4CPDE4DEPHX2
SCHEMBL12437919 0.79 TP53 (0.48) LMNAKDM4E
SCHEMBL13158777 0.79 SLC6A2 (0.46) KMT2ASMN1; SMN2ALDH1A1
SCHEMBL3109672 0.79 RORC (0.50) CYP3A4ESRRAPDE4APDE4BPDE4C
SCHEMBL13158798 0.78 SIGMAR1 (0.57)
SCHEMBL13158796 0.77 MCHR1 (0.39) PDE4APDE4BPDE4CPDE4DEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249111-A1 MULTI-RING COMPOUNDS AND USES THEREOF AVALON PHARMACEUTICALS (US) 2010-09-30 US disclosed
US-20100249111-A1 MULTI-RING COMPOUNDS AND USES THEREOF AVALON PHARMACEUTICALS (US) 2010-09-30 US disclosed
US-20100249111-A1 MULTI-RING COMPOUNDS AND USES THEREOF AVALON PHARMACEUTICALS (US) 2010-09-30 US disclosed
EP-2141994-A1 MULTI-RING COMPOUNDS AND USES THEREOF Avalon Pharmaceuticals (US) 2010-01-13 EP disclosed
WO-2008133975-A1 MULTI-RING COMPOUNDS AND USES THEREOF AVALON PHARMACEUTICALS (US) 2008-11-06 WO disclosed
WO-2008133975-A1 MULTI-RING COMPOUNDS AND USES THEREOF AVALON PHARMACEUTICALS (US) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249111-A1 MULTI-RING COMPOUNDS AND USES THEREOF TP53, BCOR, HPGDS CYP3A4 1340/4885ESRRA 1473/4885PDE4A 2355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.